Navigation Links
CSL Behring Renews Pledge to Provide Significant Funding and Donated Coagulation Factor to World Federation of Hemophilia Over 3-Year Period
Date:4/16/2012

KING OF PRUSSIA, Pa. and MONTREAL, April 16, 2012 /PRNewswire/ -- To mark World Hemophilia Day 2012, CSL Behring has again committed to making significant financial contributions and donations of clotting factor concentrate to the World Federation of Hemophilia (WFH) Global Alliance for Progress (GAP) program over the period of three years, beginning in 2012. The product donations will be made with medicine having a minimum shelf-life of one year. The goal of the WFH GAP program is to improve the diagnosis and treatment of hemophilia in developing countries. In 2009, CSL Behring was the first company to make such a three-year commitment to WFH. CSL Limited, parent company to CSL Behring, is committed to contributing to the economic, social and environmental well-being of its communities. As part of the agreement, CSL Behring will provide 2 million units of one or more of its various clotting factor products to the WFH each year for three years.

"CSL Behring is proud to be a strong supporter of the World Federation of Hemophilia and to have been a contributor to the GAP program each year since it was established," said Paul Perreault, President of CSL Behring. "We are committed to serving people who have rare and serious bleeding disorders and we will continue to work toward solutions that make a positive impact for hemophilia patients and their communities in regions of the world where those solutions are needed most."

Blood clotting factor is manufactured from purified human plasma or by using recombinant technology.

CSL Behring clotting factor is manufactured in: the Kankakee, IL, USA facility of CSL Behring; in Melbourne, Australia, at the company's Broadmeadows facility, and in Marburg, Germany.

"The product donations we receive from CSL Behring help us to support hemophilia patients in many remote areas of the world where access to these life-saving medicines is extremely challenging," sa
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CSL Behring Announces First Patient Treated in Phase III Study of Fibrinogen Concentrate (Human)(FCH) to Control Bleeding During Aortic Aneurysm Surgery
2. CSL Behring Recognized as a "Pioneer" By European Organisation for Rare Diseases (EURORDIS)
3. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
4. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
5. CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
6. CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
7. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
8. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
9. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
10. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
11. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals ... compounds that will be added to Parnell,s already ... CIMTECH Pty Ltd, a biotechnology company. The compounds ... have shown promise in bone regeneration and dermal ... develop the compounds for the veterinary market with ...
(Date:7/24/2014)... July 24, 2014  Restore Health, a leading ... pharmaceuticals, announced that it is now offering pharmacogenetics ... each individual based upon their particular genetic makeup. ... the interaction between a patient,s genetics and their ... excited to provide this new service to healthcare ...
(Date:7/24/2014)... HILDEN , Germany , and ... , Exclusive global ... assays for SF3B1 mutations, including next-generation sequencing (NGS) gene ... gene, to be targeted by new test, indicate favorable ... myelodysplastic syndromes  QIAGEN sees potential for developing ...
Breaking Medicine Technology:Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5
... a next-generation oncology diagnostics company focused on improving ... closed a $21 million series A financing. ... and included Bessemer Venture Partners, Physic Ventures and ... ) , On-Q-ity is developing diagnostics to determine ...
... 3 Reportlinker.com announces that a new ... catalogue. , Wheelchair Market Shares, ... , http://www.reportlinker.com/p0157387/Wheelchair-Market-Shares-Strategies-and-Forecasts-Worldwide-2009-to-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ... This 2009 study has 484 pages, 235 ...
Cached Medicine Technology:Cancer Diagnostics Company, On-Q-ity, Raises $21M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy 2Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 2Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 3Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 4Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 5Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 6Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 7Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 8Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 9Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 10Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 11Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 12Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 13Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 14Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 15Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 16Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 17Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 18Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 19Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 20Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 21
(Date:7/27/2014)... University scientists have shown that a powerful drug given ... only halves the early risk of rejection, but that ... drugs to be used after the operation. , The ... and presented at the World Transplant Congress in San ... difficult transplant conundrum: the powerful combinations of treatments used ...
(Date:7/27/2014)... July 27, 2014 According to a ... Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) ... Forecast, 2013-2019" the global endoscopy devices market was valued ... to grow at a CAGR of 6.8% from 2013 ... 36.9 billion in 2019. , Endoscopy procedures are performed ...
(Date:7/27/2014)... constant expansion of companies across the globe has led ... factors that have increased this demand include the application ... learning and development, security and safety, and knowledge sharing ... video market value has crossed $11.21 billion in 2013 ... with a compound annual growth rate (CAGR) of 25.97%. ...
(Date:7/27/2014)... July 27, 2014 The North American ... estimated at $1570 million in 2014, and it is ... CAGR of 4.64%. The report incorporates the factors that ... expectations of growth rates and projected total expenditure. The ... the global markets. Apart from the general overview of ...
(Date:7/27/2014)... (Sunday July 27 11:45 am ET): A ... the surgical sitehas been reduced by 77 percent ... the American College of Surgeons National Surgical Quality ... case study presented at the 2014 ACS NSQIP ... Columbia, reportedly reduced its rate of cardiac surgical ...
Breaking Medicine News(10 mins):Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 2Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 3Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 4Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 5Health News:Surgical safety program greatly reduces surgical site infections for heart operations 2Health News:Surgical safety program greatly reduces surgical site infections for heart operations 3Health News:Surgical safety program greatly reduces surgical site infections for heart operations 4
... , PALO ALTO, Calif., Aug. 10 ... will report its second quarter 2009 financial results on Tuesday, August 11, ... to discuss the results, provide guidance for 2009, and give a company ... Time. , , The live webcast and press release ...
... Aug. 10 VION PHARMACEUTICALS, INC. (OTC Bulletin ... Oncologic Drugs Advisory Committee (ODAC) Meeting at which its lead ... , , The ODAC reviews and evaluates ... human drug products for use in the treatment of cancer ...
... 10, 2009 UT Southwestern Medical Center researchers are ... track down and kill cancer cells in patients with ... Researchers are testing a tumor-specific protein called recombinant ... interact with the body,s immune system and generate a ...
... - Researchers from Indiana University,s Center for Health Policy ... government-sponsored health insurance for individuals under age 65 remains ... described or how involved the government would be. ... a government-sponsored health insurance option, such as that being ...
... help contribute to obesity among its users, according to a ... Researchers found that the average user of food stamps had ... The link between food stamps and higher weight was almost ... BMI than those not in the program, the study found. ...
... of all human cancer tumors, the Ras protein literally "drives ... Faculty of Life Sciences at Tel Aviv University. Prof. Kloog ... anti-Ras drug against pancreatic cancer, currently in clinical trials. Now, ... Journal of Pharmacology shows that the drug might be able ...
Cached Medicine News:Health News:Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin(TM) 2Health News:Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin(TM) 3Health News:UT Southwestern researchers launch study into search-and-destroy antigen for deadly skin cancer 2Health News:Americans remain divided on government involvement in health insurance, IU survey shows 2Health News:Americans remain divided on government involvement in health insurance, IU survey shows 3Health News:Food stamp use linked to weight gain, study finds 2Health News:Food stamp use linked to weight gain, study finds 3Health News:Taking the needle's sting out of diabetes 2
Inquire...
Inquire...
Inquire...
Inquire...
Medicine Products: